This is the question asked in a journalistic
article recently published by College of American
The journalist has interviewed a handful of the worlds leading kidney researchers about their outlook on a future where earlier diagnosis and management of acute kidney injury is possible. The article gives an excellent review and status update on NGAL.
Please read the article here -Read more
Dako Denmark A/S, Reagent Partnership Division, presented data and results of a validation study on The NGAL Test™ at the21st International Congress of Clinical Chemistry and Laboratory Medicine (IFCC-World Lab) in Berlin.Read more
BioPorto has CE-marked and is now launching The NGAL Test™ for diagnostic use in Europe.Read more
BioPorto Diagnostics is proud to announce a scientific poster presentation at the BRS/RA Conference in Manchester that includes data obtained with The NGAL Test...Read more
BioPorto Diagnostics announces the presentation of a new scientific study that includes data obtained with The NGAL Test - the company's forthcoming diagnostic test for acute kidney injury...Read more